PulseAugur
EN
LIVE 23:38:37

FDA approves Revolution Medicines' pancreatic cancer pill Rasonque

By PulseAugur Editorial · [1 sources] ·

The FDA has approved Rasonque, a new daily pill from Revolution Medicines, designed to target RAS protein mutations that drive tumor growth in pancreatic cancer. This approval marks a significant breakthrough, as it validates a previously considered "undruggable" mechanism and offers a substantial improvement in survival rates for patients with metastatic pancreatic adenocarcinoma. The drug demonstrated a 60% reduction in the risk of death in clinical trials, with patients living a median of 13.2 months compared to 6.7 months on standard chemotherapy. Revolution Medicines has set the list price at $39,800 for a 30-day supply, with patient assistance programs available. AI

RANK_REASON FDA approval of a new drug for a difficult-to-treat cancer. [lever_c_demoted from significant: ic=1 ai=0.0]

Read on Fortune →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

FDA approves Revolution Medicines' pancreatic cancer pill Rasonque

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
FDA approval of a new drug for a difficult-to-treat cancer. [lever_c_demoted from significant: ic=1 ai=0.0]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, model release
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
Breaking (< 6h)
Fresh story with cross-source coverage still developing. Ranking may shift as more sources report.

Full methodology in our editorial standards.

COVERAGE [1]

  1. Fortune TIER_1 English(EN) · Catherina Gioino ·

    Why Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger bet

    Dr. Danish Nagda, a shareholder in the developer, told Fortune it was "incredibly exciting ... maybe half a decade away from the post-cancer era."

RELATED ENTITIES

RELATED TOPICS